Rilpivirine

Generic Name
Rilpivirine
Brand Names
Complera, Edurant, Juluca, Odefsey, Rekambys
Drug Type
Small Molecule
Chemical Formula
C22H18N6
CAS Number
500287-72-9
Unique Ingredient Identifier
FI96A8X663
Background

Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance c...

Indication

Rilpivirine, in combination with other agents, is indicated for the treatment of HIV-1 infections in antiretroviral treatment-naive patients with HIV-1 RNA ≤100,000 copies/mL and CD4+ cell count >200 cells/mm. The FDA combination therapy approval of rilpivirine and dolutegravir is indicated for adults and adolescents 12 years of age and older weighing at lea...

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1), Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects

First Posted Date
2015-03-31
Last Posted Date
2015-03-31
Lead Sponsor
Therapeutic Concepts
Target Recruit Count
30
Registration Number
NCT02404233
Locations
🇺🇸

Therapeutic Concepts, P.A., Houston, Texas, United States

🇺🇸

Therapeutic Concepts, PA, Houston, Texas, United States

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

First Posted Date
2014-06-17
Last Posted Date
2018-08-27
Lead Sponsor
PATH
Target Recruit Count
136
Registration Number
NCT02165202
Locations
🇿🇼

Spilhaus Clinical Research Site, Belgravia, Harare, Zimbabwe

🇺🇸

Bronx Prevention Center, Bronx, New York, United States

🇿🇦

Emavundleni Clinical Research Site, Cape Town, South Africa

and more 1 locations

Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age

Phase 1
Withdrawn
Conditions
HIV Infections
Interventions
Drug: Rilpivirine
First Posted Date
2013-11-03
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT01975012

A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
Drug: Metformin
Drug: Rilpivirine
First Posted Date
2012-11-01
Last Posted Date
2014-03-06
Lead Sponsor
Janssen R&D Ireland
Target Recruit Count
20
Registration Number
NCT01719614

A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment

First Posted Date
2012-10-17
Last Posted Date
2021-02-11
Lead Sponsor
Janssen-Cilag International NV
Target Recruit Count
426
Registration Number
NCT01709084

A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Rilpivirine
Drug: Rifabutin
First Posted Date
2012-06-08
Last Posted Date
2014-03-28
Lead Sponsor
Janssen R&D Ireland
Target Recruit Count
20
Registration Number
NCT01615614

Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress

Phase 4
Completed
Conditions
Cardiovascular Disease
Interventions
Drug: Rilpivirine
Drug: Efavirenz
First Posted Date
2012-04-25
Last Posted Date
2015-08-14
Lead Sponsor
Indiana University
Target Recruit Count
40
Registration Number
NCT01585038
Locations
🇺🇸

Indiana Clinical and Translational Sciences Institute, Indianapolis, Indiana, United States

The Rilpivirine Cerebrospinal-fluid (CSF) Study

Phase 1
Completed
Conditions
HIV
Interventions
Drug: Rilpivirine
First Posted Date
2012-03-26
Last Posted Date
2014-06-19
Lead Sponsor
Imperial College London
Target Recruit Count
14
Registration Number
NCT01562886
Locations
🇬🇧

Imperial College Healthcare NHS Trust, London, United Kingdom

A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1

Phase 3
Completed
Conditions
HIV-1 Infection
Interventions
Drug: Rilpivirine
First Posted Date
2010-12-24
Last Posted Date
2021-03-04
Lead Sponsor
Janssen R&D Ireland
Target Recruit Count
482
Registration Number
NCT01266902

A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women

First Posted Date
2009-03-04
Last Posted Date
2018-07-06
Lead Sponsor
Janssen Scientific Affairs, LLC
Target Recruit Count
77
Registration Number
NCT00855335
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy